Characteristics of all CML patients attempting TFR with ≥12 months of follow-up (n = 115)
| Patient characteristic . | Patients attempting TFR with ≥12-mo follow-up No. (%) or median [range] . |
|---|---|
| Male | 61 (53.0) |
| Age at TFR attempt, y | 60.9 [33.4-89.8] |
| Sokal score | |
| Low-risk (<0.8) | 49 (42.6) |
| Intermediate-risk (0.8-1.2) | 41 (35.7) |
| High-risk (>1.2) | 17 (14.8) |
| Not available | 8 (7.0) |
| ELTS score | |
| Low-risk (≤1.5680) | 72 (63.2) |
| Intermediate-risk (>1.5680-≤2.2185) | 26 (22.4) |
| High-risk (>2.2185) | 8 (6.4) |
| Not available | 9 (8.0) |
| Transcript type | |
| e14a2 | 51 (44.3) |
| e13a2 | 43 (37.4) |
| Both e14a2 and e13a2 | 20 (17.4) |
| e1a2 | 1 (0.9) |
| Time to MR4.5, y | 2.2 [0.2-13.2] |
| Duration of MR4.5, y | 3.3 [2.0-12.5] |
| Duration of TKI therapy, y | 7.0 [3.0-17.6] |
| First-line treatment | |
| Imatinib | 89 (77.4) |
| 2G-TKI | 17 (14.8) |
| Other (interferon/autograft) | 9 (7.8) |
| Therapy ceased | |
| Imatinib | 70 (60.9) |
| First-line 2G-TKI, nilotinib/dasatinib, or 2G-TKI for imatinib-intolerance | 37 (32.2) |
| 2G-TKI following imatinib failure | 8 (7.0) |
| Baseline BCR-ABL1IS value available | 111 (96.5) |
| EMR achieved | 98 (90.7) |
| 3-mo BCR-ABL1 value available | 108 (93.9) |
| BCR-ABL1IS >10% | 10 (9.3) |
| BCR-ABL1IS >1%-10% | 28 (25.9) |
| BCR-ABL1IS >0.1%-1% | 43 (39.8) |
| BCR-ABL1IS ≤0.1% | 27 (25.0) |
| 3-mo halving time able to be calculated | 102 (88.7) |
| Median halving time (d) | 13.95 [3.6-267.8] |
| 3-mo BCR-ABL1 fold-reduction able to be calculated | 102 (88.7) |
| Median 3-mo BCR-ABL1 fold-reduction | 125.5 [3.1-8700] |
| Months between baseline and 3-mo BCR-ABL1 value | 3.1 [2.0-3.9] |
| 12-mo BCR-ABL1 value available | 112 (97) |
| MMR achieved | 86 (76.8) |
| Patient characteristic . | Patients attempting TFR with ≥12-mo follow-up No. (%) or median [range] . |
|---|---|
| Male | 61 (53.0) |
| Age at TFR attempt, y | 60.9 [33.4-89.8] |
| Sokal score | |
| Low-risk (<0.8) | 49 (42.6) |
| Intermediate-risk (0.8-1.2) | 41 (35.7) |
| High-risk (>1.2) | 17 (14.8) |
| Not available | 8 (7.0) |
| ELTS score | |
| Low-risk (≤1.5680) | 72 (63.2) |
| Intermediate-risk (>1.5680-≤2.2185) | 26 (22.4) |
| High-risk (>2.2185) | 8 (6.4) |
| Not available | 9 (8.0) |
| Transcript type | |
| e14a2 | 51 (44.3) |
| e13a2 | 43 (37.4) |
| Both e14a2 and e13a2 | 20 (17.4) |
| e1a2 | 1 (0.9) |
| Time to MR4.5, y | 2.2 [0.2-13.2] |
| Duration of MR4.5, y | 3.3 [2.0-12.5] |
| Duration of TKI therapy, y | 7.0 [3.0-17.6] |
| First-line treatment | |
| Imatinib | 89 (77.4) |
| 2G-TKI | 17 (14.8) |
| Other (interferon/autograft) | 9 (7.8) |
| Therapy ceased | |
| Imatinib | 70 (60.9) |
| First-line 2G-TKI, nilotinib/dasatinib, or 2G-TKI for imatinib-intolerance | 37 (32.2) |
| 2G-TKI following imatinib failure | 8 (7.0) |
| Baseline BCR-ABL1IS value available | 111 (96.5) |
| EMR achieved | 98 (90.7) |
| 3-mo BCR-ABL1 value available | 108 (93.9) |
| BCR-ABL1IS >10% | 10 (9.3) |
| BCR-ABL1IS >1%-10% | 28 (25.9) |
| BCR-ABL1IS >0.1%-1% | 43 (39.8) |
| BCR-ABL1IS ≤0.1% | 27 (25.0) |
| 3-mo halving time able to be calculated | 102 (88.7) |
| Median halving time (d) | 13.95 [3.6-267.8] |
| 3-mo BCR-ABL1 fold-reduction able to be calculated | 102 (88.7) |
| Median 3-mo BCR-ABL1 fold-reduction | 125.5 [3.1-8700] |
| Months between baseline and 3-mo BCR-ABL1 value | 3.1 [2.0-3.9] |
| 12-mo BCR-ABL1 value available | 112 (97) |
| MMR achieved | 86 (76.8) |
EMR, early molecular response; ELTS, EUTOS long-term survival.